Citi Downgrades Illumina to Neutral with Target Price Cut to $165
Dec 13, 2024 16:12
CST Updated
16:12
Illumina
Diagnostic Product Developer
Gelonghui December 13 | Citi: Downgraded Illumina's target price from $190 to $165, and downgraded the rating from "Buy" to "Neutral". (Gelonghui)